Answers are grounded in this paper and cite their sources.
Investigates CO release for tumor treatment in cancer models, suggesting a new approach for immunotherapy.
Malignant tumors remain a leading cause of premature death worldwide, with disproportionately increasing burdens in resource-limited regions. Although immune checkpoint blockade (ICB) has emerged as a transformative cancer therapy, its efficacy is often limited by the immunosuppressive tumor microenvironment (TME). Leveraging iron as the most abundant bioactive transition metal in Earth’s crust, we report F-Fe, a complex IV-targeted carbon monoxide-releasing molecule (CORM) that is activated by a clinically approved dental light-curing unit to induce pyroptosis for reprogramming the TME. We developed a bioinspired delivery system named GLEAM to facilitate clinical applications that adhere to tissue surfaces while channeling light into deeper tissue for on-target CO release, simultaneously providing real-time visual feedback for treatment monitoring. Murine oral and breast cancer models validated the therapeutic efficacy, showing significant tumor suppression and TME remodeling. When combined with αPD-1 therapy, it markedly suppressed metastasis, prevented recurrence, and prolonged survival. Our findings suggest that Fe-based small molecules with biomimetic delivery can leverage dental light to boost ICB efficacy, offering a sustainable and translational approach to tumor treatment.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: